Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development
- PMID: 8803903
Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development
Abstract
A wide variety of mechanisms of anti-rheumatic action have been proposed for anti-malarial agents. The molecular actions of chloroquine have been most thoroughly studied in vitro and in vivo, but it is likely that hydroxychloroquine works by a similar mechanism. Both agents are weak diprotic bases that can pass through the lipid cell membrane and preferentially concentrate in acidic cyto-plasmic vesicles. The resulting slight elevation of pH within these vesicles in macrophages or other antigen-presenting cells may influence the immune response to autoantigens. We hypothesize that anti-malarial agents influence the association of autoantigenic peptides with class II MHC molecules in the compartment for peptide loading and/or the subsequent processing and transport of the peptide-MHC complex to the cell membrane. This model of anti-malarial action provides a method to test additional drugs for their ability to modulate the immune response.
Similar articles
-
Mechanism of action of antimalarial drugs: inhibition of antigen processing and presentation.Lupus. 1993 Feb;2 Suppl 1:S9-12. Lupus. 1993. PMID: 8097945 Review.
-
Synergy between lysosomotropic amines and cyclosporin A on human T cell responses to an exogenous protein antigen, tetanus toxoid.Bone Marrow Transplant. 1996 Sep;18(3):625-31. Bone Marrow Transplant. 1996. PMID: 8879628
-
Mechanism of action of hydroxychloroquine as an antirheumatic drug.Semin Arthritis Rheum. 1993 Oct;23(2 Suppl 1):82-91. doi: 10.1016/s0049-0172(10)80012-5. Semin Arthritis Rheum. 1993. PMID: 8278823
-
Class II MHC/peptide complexes are released from APC and are acquired by T cell responders during specific antigen recognition.J Immunol. 1999 Nov 15;163(10):5201-10. J Immunol. 1999. PMID: 10553040
-
Peptide binding and antigen presentation by class II histocompatibility glycoproteins.Biopolymers. 1997;43(4):303-22. doi: 10.1002/(SICI)1097-0282(1997)43:4<303::AID-BIP4>3.0.CO;2-Z. Biopolymers. 1997. PMID: 9316394 Review.
Cited by
-
Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.Rheumatology (Oxford). 2017 Apr 1;56(suppl_1):i100-i113. doi: 10.1093/rheumatology/kew417. Rheumatology (Oxford). 2017. PMID: 28375452 Free PMC article. Review.
-
Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus.Arthritis Rheumatol. 2014 Sep;66(9):2532-2544. doi: 10.1002/art.38703. Arthritis Rheumatol. 2014. PMID: 24838349 Free PMC article.
-
Inhibiting TLR7 Expression in the Retinal Pigment Epithelium Suppresses Experimental Autoimmune Uveitis.Front Immunol. 2022 Jan 5;12:736261. doi: 10.3389/fimmu.2021.736261. eCollection 2021. Front Immunol. 2022. PMID: 35069523 Free PMC article.
-
Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes.Eur J Med Chem. 2020 May 1;193:112238. doi: 10.1016/j.ejmech.2020.112238. Epub 2020 Mar 17. Eur J Med Chem. 2020. PMID: 32203790 Free PMC article. Review.
-
Molecular effects and retinopathy induced by hydroxychloroquine during SARS-CoV-2 therapy: Role of CYP450 isoforms and epigenetic modulations.Eur J Pharmacol. 2020 Nov 5;886:173454. doi: 10.1016/j.ejphar.2020.173454. Epub 2020 Aug 4. Eur J Pharmacol. 2020. PMID: 32763298 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Research Materials